Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 17Magnetic Resonance Spectroscopy 15Gemcitabine 13Cisplatin 8Biopsy 8Radiotherapy 7Mitomycin 6Cystoscopy 6pembrolizumab 5Trastuzumab 5Paclitaxel 5Fluorouracil 5cabozantinib 4atezolizumab 4Radiation 4erdafitinib 3dehydroftorafur 3Transurethral Resection of Bladder 3Sunitinib 3Sorafenib 3Platinum 3Nivolumab 3Mitozytrex 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3valrubicin 2tipifarnib 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urinary Bladder Neoplasms × Contrast Media × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡